Cumberland Pharmaceuticals Inc (CPIX) - Financial and Strategic SWOT Analysis Review
Description
Cumberland Pharmaceuticals Inc (CPIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. It acquires, develops, and commercializes branded prescription products that target hospital acute care, gastroenterology, and oncology markets through small, specialized sales teams. The company’s portfolio includes treatments for various conditions, such as Acetadote for acetaminophen poisoning, Caldolor for pain and fever, and Kristalose for constipation. It also offers Omeclamox-Pak for Helicobacter pylori infection, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia, and Vibativ for serious bacterial infections. Cumberland is advancing its pipeline with ifetroban, a selective thromboxane-prostanoid receptor antagonist which has received orphan drug and rare pediatric disease designations for treating cardiomyopathy associated with Duchenne muscular dystrophy. Ifetroban is also being studied for systemic sclerosis, idiopathic pulmonary fibrosis, and other conditions. Cumberland is headquartered in Nashville, Tennessee, the US.
Cumberland Pharmaceuticals Inc Key Recent Developments
Apr 28,2026: Cumberland Pharmaceuticals to Announce Q1 2026 Financial Results & Company Update
Apr 23,2026: Cumberland Pharmaceuticals Announces Transaction to Integrate Commercial Business With Apotex
Apr 16,2026: Cumberland Pharmaceuticals Announces Expanded Indication for Caldolor (Ibuprofen) Injection and Launches New Brand Website
Mar 03,2026: Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Opportunities thaented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. It acquires, develops, and commercializes branded prescription products that target hospital acute care, gastroenterology, and oncology markets through small, specialized sales teams. The company’s portfolio includes treatments for various conditions, such as Acetadote for acetaminophen poisoning, Caldolor for pain and fever, and Kristalose for constipation. It also offers Omeclamox-Pak for Helicobacter pylori infection, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia, and Vibativ for serious bacterial infections. Cumberland is advancing its pipeline with ifetroban, a selective thromboxane-prostanoid receptor antagonist which has received orphan drug and rare pediatric disease designations for treating cardiomyopathy associated with Duchenne muscular dystrophy. Ifetroban is also being studied for systemic sclerosis, idiopathic pulmonary fibrosis, and other conditions. Cumberland is headquartered in Nashville, Tennessee, the US.
Cumberland Pharmaceuticals Inc Key Recent Developments
Apr 28,2026: Cumberland Pharmaceuticals to Announce Q1 2026 Financial Results & Company Update
Apr 23,2026: Cumberland Pharmaceuticals Announces Transaction to Integrate Commercial Business With Apotex
Apr 16,2026: Cumberland Pharmaceuticals Announces Expanded Indication for Caldolor (Ibuprofen) Injection and Launches New Brand Website
Mar 03,2026: Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Opportunities thaented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
50 Pages
- Section 1 - About the Company
- Cumberland Pharmaceuticals Inc - Key Facts
- Cumberland Pharmaceuticals Inc - Key Employees
- Cumberland Pharmaceuticals Inc - Key Employee Biographies
- Cumberland Pharmaceuticals Inc - Major Products and Services
- Cumberland Pharmaceuticals Inc - History
- Cumberland Pharmaceuticals Inc - Company Statement
- Cumberland Pharmaceuticals Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Cumberland Pharmaceuticals Inc - Business Description
- R&D Overview
- Cumberland Pharmaceuticals Inc - Corporate Strategy
- Cumberland Pharmaceuticals Inc - SWOT Analysis
- SWOT Analysis - Overview
- Cumberland Pharmaceuticals Inc - Strengths
- Cumberland Pharmaceuticals Inc - Weaknesses
- Cumberland Pharmaceuticals Inc - Opportunities
- Cumberland Pharmaceuticals Inc - Threats
- Cumberland Pharmaceuticals Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Cumberland Pharmaceuticals Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Apr 28, 2026: Cumberland Pharmaceuticals to Announce Q1 2026 Financial Results & Company Update
- Apr 23, 2026: Cumberland Pharmaceuticals Announces Transaction to Integrate Commercial Business With Apotex
- Apr 16, 2026: Cumberland Pharmaceuticals Announces Expanded Indication for Caldolor (Ibuprofen) Injection and Launches New Brand Website
- Mar 03, 2026: Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth
- Dec 08, 2025: Caldolor (Ibuprofen) Injection J-Code Associated With Reimbursement Price, Cumberland Pharmaceuticals Inc.
- Oct 20, 2025: Cumberland Pharmaceuticals Expands Commercial Portfolio with FDA Approved Product
- Oct 20, 2025: RedHill's Talicia Secures $4 Million Strategic Investment and Co-Commercialization Partnership
- Oct 13, 2025: Cumberland Pharmaceuticals' Vibativ Added To National Group Purchasing Agreement With Premier, Inc.
- Oct 01, 2025: Cumberland Pharmaceuticals Receives Product Approval in Mexico
- Mar 04, 2025: Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Cumberland Pharmaceuticals Inc, Key Facts
- Cumberland Pharmaceuticals Inc, Key Employees
- Cumberland Pharmaceuticals Inc, Key Employee Biographies
- Cumberland Pharmaceuticals Inc, Major Products and Services
- Cumberland Pharmaceuticals Inc, History
- Cumberland Pharmaceuticals Inc, Subsidiaries
- Cumberland Pharmaceuticals Inc, Key Competitors
- Cumberland Pharmaceuticals Inc, Ratios based on current share price
- Cumberland Pharmaceuticals Inc, Annual Ratios
- Cumberland Pharmaceuticals Inc, Annual Ratios (Cont...1)
- Cumberland Pharmaceuticals Inc, Annual Ratios (Cont...2)
- Cumberland Pharmaceuticals Inc, Interim Ratios
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Cumberland Pharmaceuticals Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Cumberland Pharmaceuticals Inc, Performance Chart (2021 - 2025)
- Cumberland Pharmaceuticals Inc, Ratio Charts
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

